Skip to main content

Table 2 Twelve cases with 13 major discrepancies

From: Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience

Case ID

Diagnosis

Outside lab antibody

Laboratory

ER NEG/POS (%)a

PR NEG/POS (%)a

Outside

In-house

Outside

In-house

1

IDC

Unknown

International

NEG (< 1)

NEG (0)

NEG (< 1)

POS (1)

2

IDC

ER-monoclonal mouse antibody, clone ID5-α

PR-monoclonal mouse antibody, clone PgR 636

Reference

NEG (0)

POS (3)

NEG (0)

NEG (0)

3

ILC

ER-GF11, Leica

PR-1294, DAKO

Community

NEG (0)

NEG (< 1)

NEG (0)

POS (11)

4

IDC

ER-SP1 monoclonal, Ventana

PR-1E2 monoclonal, Ventana

Community

NEG (0)

NEG (0)

NEG (0)

POS (1)

5

IDC

ER-SP1 monoclonal, Ventana

PR-1E2 monoclonal, Ventana

Community

NEG (0)

POS (1)

NEG (0)

NEG (0)

6

IDC

ER-SP1 monoclonal, Ventana

PR-1E2 monoclonal, Ventana

Community

NEG (< 1)

NEG (0)

NEG (< 1)

POS (5)

7

IDC

Unknown

Reference

NEG (< 1)

POS (2)

NEG (0)

NEG (0)

8

IDC

ER-SP1 monoclonal

PR-1E2 monoclonal

Community

NEG (0)

NEG (0)

NEG (0)

POS (2)

9b

IDC

ER-SP1 monoclonal

PR-1E2 monoclonal

Reference

NEG (< 1)

POS (2)

NEG (< 1)

POS (5)

10

IDC

ER-Monoclonal 6F11

PR-monoclonal mouse antibody, clone PgR 636

Community

NEG (< 1)

POS (15)

NEG (< 1)

NEG (< 1)

11

IDC

ER-SP1 monoclonal

PR-1E2 monoclonal

Community

NEG (0)

NEG (0)

NEG (0)

POS (5)

12

IDC

Unknown

International

NEG (< 1)

NEG (0)

NEG (< 1)

POS (10)

  1. ER estrogen receptor, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, NEG negative, POS positive, PR progesterone receptor
  2. aPercentage of cells that stained for ER or PR
  3. bDiscrepancy in both ER and PR